Nirav N. Shah, MD

Nirav N. Shah, MD, is an associate professor of medicine in the Division of Hematology and Oncology at Medical College of Wisconsin.

Articles

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCL

March 21st 2025

Zamtocabtagene autoleucel was associated with a manageable safety profile with no grade 3 or higher CRS and low ICANS rates in relapsed/refractory DLBCL.

Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCL

March 1st 2025

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

Dr Shah on Efficacy Data for Zamto-Cel in R/R DLBCL

February 14th 2025

Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma

Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCL

September 1st 2023

Nirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.

Dr Shah on the Investigation of Split-Dose R-CHOP in DLBCL

August 31st 2023

Nirav N. Shah, MD, discusses primary outcomes from a phase 2 trial investigating split-dose R-CHOP in older patients with diffuse large B-cell lymphoma.

Dr Shah on the Background of the BRUIN Trial in Relapsed/Refractory MCL

July 28th 2023

Nirav N. Shah, MD, discusses the background of the phase 1/2 BRUIN trial of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma.

Dr Shah on Long-Term Survival Data For Pirtobrutinib in BTK Inhibitor–Pretreated R/R MCL

June 16th 2023

Nirav N. Shah, MD, discusses the long-term efficacy of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma with previous exposure to covalent BTK inhibitors, according to updated data from the phase 1/2 BRUIN trial.

Dr Shah on the Investigation of LV20.19 CAR in MCL

April 5th 2023

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr. Shah on Zamto-cel in R/R DLBCL

March 10th 2023

Nirav N. Shah, MD, discusses findings from a preplanned interim futility analysis of the single-arm phase 2 DALY II USA trial in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Shah on the Safety of LV20.19 CAR T-cell Therapy in R/R MCL

March 6th 2023

Nirav N. Shah, MD, discusses the safety of the lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens, as well as future efforts from a phase 1/2 study of the product in patients with relapsed/refractory mantle cell lymphoma.

Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL

February 16th 2023

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies

November 28th 2022

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Dr. Shah on How to Address CAR T-Cell Therapy Failure in Hematologic Malignancies

August 16th 2022

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Dr. Shah on the Safety of a Novel Dual-Targeted CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 14th 2021

Nirav Shah, MD, MCW, discusses the safety profile of an anti-CD20/anti-CD19 CAR T-cell therapy under investigation in the treatment of patients with non-Hodgkin lymphoma.

Dr. Shah on the Rationale for Tandem Receptor CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 11th 2021

Nirav N. Shah, MD, discusses the rationale to evaluate tandem receptor CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Shah on Dosing Tandem Receptor CAR T-Cell Therapy in B-Cell Malignancies

December 3rd 2020

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the dosing of tandem receptor CAR T-cell therapy in B-cell malignancies.

Dr. Shah on Differences Between Anti-CD19 CAR T-Cell Therapies

May 30th 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Dr. Shah Discusses Ongoing Research With CAR T-Cell Therapy

May 2nd 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.